Wells Fargo raised the firm’s price target on HCA Healthcare (HCA) to $481 from $452 and keeps an Equal Weight rating on the shares. The firm cites in-line Q4 2025 results and better-than-expected 2026 guidance, with upside vs. its previous estimates driven by a stronger “core” growth assumption, modestly lower gross exchange headwind, and modestly larger offsets.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $555 from $525 at RBC Capital
- HCA Healthcare price target raised to $529 from $490 at TD Cowen
- HCA Healthcare price target raised to $598 from $525 at UBS
- HCA Healthcare price target raised to $540 from $500 at Oppenheimer
- HCA Healthcare price target raised to $588 from $525 at Cantor Fitzgerald